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Rocky Flats Beryllium Health Surveillance
Arthur W. Stange,1 F. Joseph Furman,2 and Duane E. Hilmas"
1Health Effects Department, 2Occupational Medicine Department, Rocky
Flats Environmental Technology Site, Golden, Colorado
The Rocky Flats Beryllium Health Surveillance Program (BHSP), initiated in June 1991, was
designed to provide medical surveillance for current and former employees exposed to beryllium.
The BHSP identifies individuals who have developed beryllium sensitivity using the beryllium
lymphocyte proliferation test (BeLPT). A detailed medical evaluation to determine the prevalence of
chronic beryllium disease (CBD) is offered to individuals identified as beryllium sensitized or to those
who have chest X-ray changes suggestive of CBD. The BHSP has identified 27 cases of CBD and
another 74 cases of beryllium sensitization out of 4268 individuals tested. The distribution of BeLPT
values for normal, sensitized, and CBD-identified individuals is described. Based on the information
collected during the first 3 1/3 years of the BHSP, the BeLPT is the most effective means for the
early identification of beryllium-sensitized individuals and to identify individuals who may have CBD.
The need for BeLPT retesting is demonstrated through the identification of beryllium sensitization in
individuals who previously tested normal. Posterior/anterior chest X-rays were not effective in the
identification of CBD. - Environ Health Perspect 104(Suppl 5):981-986 (1996)
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Introduction
Chronic beryllium disease (CBD) is a
chronic granulomatous disorder of the
lungs following inhalation ofberyllium, in
which a specific cell-mediated immune
response plays a central role (1-3). The
pathogenesis of CBD is believed to be a
cell-mediated hypersensitivity reaction to
beryllium bound to tissue proteins. Hyper-
sensitivity to beryllium demonstrated
through the beryllium lymphocyte prolifer-
ation test (BeLPT) is one ofthe criteria for
the diagnosis ofCBD (1-3).
Rocky Flats, 16 miles northwest of
Denver, Colorado, part of the U.S.
Department of Energy (DOE) nuclear
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weapons complex, began using beryllium
in research and development operations in
1953. Beryllium production began in
1957. In June 1984, the first case of CBD
at Rocky Flats was diagnosed in a beryl-
lium machinist. The potential for occupa-
tional beryllium exposure occurred to
varying degrees in a wide variety ofjobs at
Rocky Flats.
This article describes an ongoing volun-
tary program to assess beryllium sensitiza-
tion and CBD in current and former Rocky
Flats employees. The Beryllium Health
Surveillance Program (BHSP) used the
BeLPT for the detection ofberyllium sensi-
tization, B-reader* evaluated posterior/ante-
rior chest X-rays, and medical evaluations at
two major medical centers with experience
in diagnosing CBD. Beginning in August
1993, the BHSP began providing BeLPT
retesting for all employees who previously
had tested BeLPT normal or had received
an abnormal chest X-ray possibly related to
CBD. The BHSP has identified beryllium
sensitization in individuals who previously
tested BeLPT negative. The BHSP has also
demonstrated the need to confirm positive
*B1-readers are physicians trained and certified by the
National Institute of Occupational Safety and Health
(OSHA) in the use of the International Labor Office
(ILO) system for classifying radiographs for the
presence of pneumoconioses.
BeLPT results prior to offering a more
involved medical evaluation for the diagnosis
ofCBD.
Methods
Surveillance Population Identification
The BHSP is a voluntary participation pro-
gram implemented in June 1991 and is
offered to current and former employees of
prime contractors, subcontractors, DOE,
and various temporary Crafts and Trades
Union employees ofRocky Flats.
Prior to the implementation of the
BHSP, 23 cases of CBD had been identi-
fied in current and former Rocky Flats
employees. Three cases of CBD had been
identified by periodic chest X-ray and
symptom surveillance. Using the BeLPT as
a screening tool investigators had identified
four CBD cases in a pilot study of beryl-
lium-exposed workers (2). The BeLPT and
chest X-ray were used to identify 16 cases
of CBD in a stratified population of
employees (4). Since one ofthese cases was
in an employee who had no identifiable
contact with beryllium, any individual who
self-identified with the potential for expo-
sure to beryllium was allowed to participate
in the BHSP.
The Beryllium Lymphocyte
Proliferation Test
The peripheral blood BeLPT, which mea-
sures lymphocyte proliferation in response
to beryllium salts (beryllium sulfate, beryl-
lium fluoride) in vitro, is elevated in indi-
viduals with beryllium disease and in those
sensitized to beryllium (1-3,5,6). The use
of bronchoalveolar lavage (BAL) lympho-
cytes in the BeLPT has aided the diagnosis
ofberyllium sensitization and the diagnosis
ofCBD (1).
The BeLPT was used to identify beryl-
lium-sensitized individuals in the BHSP.
Three laboratories with recognized exper-
tise in performing BeLPTs analyzed sub-
mitted peripheral blood specimens. An
individual was considered beryllium sensi-
tized when two consecutive or concurrent
peripheral blood BeLPTs were found to be
positive. An individual was also listed as
sensitized to beryllium if the BAL BeLPT
was positive but the peripheral blood
BeLPT was negative. The use of two posi-
tive BeLPTs for the identification of sensi-
tivity was done to reduce the number of
false positives and to minimize unnecessary
medical evaluations for CBD.
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Beryllium Health Surveillance
ProgramTesting
Current and former employees of Rocky
Flats participated in the BHSP ifthey indi-
cated a potential for exposure to beryllium
during their employment at the site. Each
participant signed an informed consent
document and completed a self-adminis-
tered questionnaire containing medical and
occupational history questions. Participants
received a venipuncture with 30 ml ofblood
collected for the peripheral blood BeLPT
(60-90 ml collected for quality control
specimens), and a posterior/anterior chest
X-ray for B-reader review.
A quality-control program was imple-
mented to monitor the results from the
three BeLPT laboratories, and to monitor
the occurrence of false-positive BeLPT
results. Individuals participating in the
BHSP were selected at random to serve as
quality controls. When blood samples were
redrawn for confirmational BeLPT from
individuals who received a positive result
on their initial BeLPT, specimens of the
second blood test were sent to either one or
two additional BeLPT laboratories.
Analysis of quality-control BeLPT results
included all specimens submitted from
January 1992 through October 1994.
To examine the occurrence of false-
positive BeLPT results, data were compared
for all individuals who received an initial
positive test and received a confirmational
BeLPT. Only confirmational results from
BeLPTs performed within 1 year of the
date of the original positive finding were
included in the comparison. A comparison
was done to determine if the value of the
initial positive BeLPT had any relationship
to the percentage ofconfirmational BeLPT
results that were positive or negative.
Posterior/anterior chest X-rays were
evaluated according to the International
Labor Office (ILO) classification system for
radiographs ofpneumoconioses by board-
certified radiologists who were certified B-
readers (7). Abnormal profusion ofsmall
opacities was defined as profusion greater
than or equal to 1/0. Participants with a
chest X-ray abnormality possibly associated
with CBD, profusion 1/0 or greater, were
contacted and informed of the availability
of additional diagnostic procedures for a
determination ofCBD. Participants with a
profusion of 0/1 were offered a 1-year
BeLPT retest and a chest X-ray to deter-
mine if changes occurred in their BeLPT
results or in their profusion rating.
As part of an X-ray quality assurance
program, chest X-rays found to have an
abnormality not associated with CBD,
chest X-rays with an abnormality possibly
associated with CBD, and a 5% random
sample ofall normal chest X-rays were sent
to another board-certified B-reader radiology
group for a second review.
MedicalEvaluations forChronic
Beryllium Disease
Beryllium-sensitized individuals and indi-
viduals with a small-opacity profusion of
1/0 or greater on chest X-ray were offered a
detailed medical evaluation for CBD
including but not limited to exercise pul-
monary physiology testing; computerized
axial tomography; bronchoscope for BAL
(for the collection oflung lymphocytes for
the BeLPT), and transbronchial lung biopsy
to assess the presence of granulomatous
disease.
In the BHSP, a definitive diagnosis of
CBD requires a history of exposure to
beryllium, a positive peripheral blood
BeLPT, a positive lung lavage BeLPT
result, and histologic evidence of pul-
monary granulomatous disease. A probable
diagnosis of CBD generally includes evi-
dence of granulomatous disease by chest
X-ray or CT scan, a positive peripheral
blood BeLPT, and a history ofexposure to
beryllium or relevant documentation of
beryllium exposure.
Three-Year Beryllium Health
Surveillance Program Retesting
In August 1993, the DOE approved
BeLPT retesting for current Rocky Flats
employees who had not been tested for 3
years or more and who previously had
tested BeLPT negative. Current and for-
mer employees were also offered a 1-year
BeLPT retest and chest X-ray if they had
an unconfirmed positive BeLPT result or a
chest X-ray with a small opacity profusion
rating of 0/1. Individuals with a profusion
of small opacities of 1/0 or greater who
completed a clinical evaluation for CBD,
but for whom no definitive diagnosis was
reached, were offered a 1-year BeLPT
retest and chest X-ray.
Periodic BeLPT retesting allows for the
identification of BeLPT-negative-to-posi-
tive conversions, and also identifies false-
negative BeLPT results. Determining
which BeLPT retest results are BeLPT-neg-
ative-to-positive conversions and which are
the identification ofprevious false-negative
BeLPT results is not possible by use ofthe
blood test alone. CBD medical evaluations
would be required to definitively identify
false-negative BeLPT results.
Table 1. Beryllium health surveillance population.
Status
Current Rocky Flats employees contacted
Participation forms returned
Requested participation
Initial BeLPT completed
CBD
BeLPT positive (sensitized)
Employees contacted 3-year BeLPT retest
Requested participation
3-year BeLPT completed
CBD
BeLPT positive (sensitized)
Former Rocky Flats employees contacted
Participation forms returned
Requested participation
Initial BeLPT completed
CBD
BeLPT positive (sensitized)
Employees contacted 1-year BeLPT retest
Requested participation
1-year BeLPT completed
CBD
BeLPT positive (sensitized)
No.
8772
3902
(44.5%)
1932
(49.5%)
1805
6
21
395
347
347
7
9865
3602
(36.5%)
2826
(78.5%)
2463
20
44
25
25
25
0
2
Results
Demographics
The BHSP surveillance population is char-
acterized in Table 1. From June 1991
through October 1994, 8772 current Rocky
Flats employees were sent BHSP participa-
tion forms; 44% (n=3902) returned the
form. Of those returned, 49.5% (n=1932)
indicated a desire to participate. From
August 1993 through October 1994, 395
current Rocky Flats employees were con-
tacted regarding 1-year/3-year BeLPT
retesting. Of those eligible for retesting
88% (n=347) requested participation.
From June 1991 through October
1994, 9865 former employees of Rocky
Flats were sent BHSP participation forms;
37% (n=3602) returned the form, and of
those 78.5% (n=2826) indicated a desire
to participate. From August 1993 through
October 1994, 25 former Rocky Flats
employees were contacted regarding 1-year/
3-year BeLPT retesting. All ofthose eligible
for retesting requested participation.
ChronicBerylium Disease and
Beryllium Sensitization Cases
Beryllium sensitization and CBD cases
were diagnosed in people who held a wide
variety of jobs at Rocky Flats (Table 2).
Some of these workers had been identified
as susceptible in an earlier beryllium health
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study at Rocky Flats (4). New cases ofCBD
and beryllium sensitization were identified
in workers with minimal opportunity for
exposure to beryllium.
Between June 1991 and October 1994,
1805 current Rocky Flats employees
received their initial BeLPT as participants
in the BHSP. Seven cases of CBD were
diagnosed in current employees, and 28
current employees were identified as beryl-
lium sensitized (Table 1). During the same
period, 2463 former employees received
BeLPT as participants in the BHSP. Of
this group, 20 individuals were diagnosed
with CBD and 46 former employees were
identified as beryllium sensitized (Table 1).
Individuals identified as sensitized have
diagnostic evaluations for CBD in progress.
A statistically significant difference
(p<0.001) was found in the mean time
from first identified beryllium exposure to
the diagnosis ofCBD in current employees
(mean 22.1 years) versus former employees
(mean 28.7 years), and a statistically
significant difference (p<0.001) was found
in the mean time from first identified beryl-
lium exposure to the identification ofberyl-
lium sensitization in current employees
Table 2. Current and former workers with CBD and
CBD sensitization.
Status ofworkers
CBD Sensitization
Job title diagnosed identified
Machinist 4 8
Electrician 3 4
Chemicaloperatora 3 2
Radiological protection 3 2
technician
Janitor/laborer 2 8
Engineer 2 7
Clerical/secretarial 2 5
Sheet metal worker 2 4
Laboratory technician 1 4
Tool maker/tool grinder 1 3
Chemist/chemicalengineer 1 2
Airfiltertechnician 1 1
Guard/safetyinspector 1 1
Metallurgical operator 1 1
Administrative/managerial 4
Pipefitter 4
Clerkpacker 3
Parts inspector 2
Metallurgist/metallurgical 2
analyst
Quality assurance inspector/ 2
engineer
Carpenter 1
Equipment operator 1
Stationary operating engineer 1
Technical support 1
Total 27 74
aJobs in italics indicate those with minimal opportunity
for exposure to beryllium.
Table 3. Current and former CBD and sensitized cases.
Years between first CBD diagnosed Sensitization identified
identified exposure to Employee status Employee status
beryllium and diagnosis Current Former Current Former
0-10 0 0 6 3
11-20 3 2 15 5
21-30 3 13 6 18
31-40 1 5 1 19
41+ 0 0 0 1
Total cases 7 20 28 46
Mean years between first
identified exposure to
beryllium and diagnosis 22.1 28.7 16.7 27.7
(mean 16.7 years) versus former employees
(mean 27.7 years). The relative distribution
ofthese cases is shown in Table 3.
The total sensitization rate (CBD and
sensitized cases) for the tested cohort
(n=4268) was 2.3%. The CBD rate was
0.6% and the beryllium sensitization rate
was 1.7%. These rates are comparable to
rates previously reported in studies of
beryllium-exposed workers.
Three-year BeLPT retesting has resulted
in the identification of one case of CBD
and nine cases of beryllium sensitization
out ofthe 372 current and former employ-
ees retested (Table 4). The total sensitiza-
tion rate (CBD and sensitized cases) for the
3-year retest cohort of2.7% is not statisti-
cally different from the rate observed from
initial BeLPT findings. After completing
CBD medical evaluations, one of these
individuals was diagnosed with CBD, and
Table 4.Three-year BeLPT retesting, August 1993 to
October 1994.
Current Former
employees employees Total
No. tested 347 25 372
Outcome
CBD diagnosed 1 0 1
Sensitized 7 2 9
% CBD/sensitization 2.3% 8.0% 2.7%
conversion
the nine remaining sensitized individuals
will be offered an annual CBD medical
evaluation.
Current employees of Rocky Flats who
were identified as sensitized to beryllium or
who were diagnosed with CBD were
notified of the potential hazards related to
further exposure to beryllium. These
employees were removed from work areas
where there was the potential for exposure
to beryllium. Sensitized individuals are
offered annual medical evaluations to
monitor for the development of CBD.
Individuals diagnosed with CBD are
offered annual medical evaluations to mon-
itor the progression of the disease and to
provide treatment where appropriate.
BerylliumLymphocyte Proliferation
TestQualityControl Program
The BHSP BeLPT Quality Control
Program was designed to monitor the
results of the BeLPTs performed at the
three BeLPT laboratories. Tables 5 and 6
show the results ofsplit-sampling testing
between laboratories. For all BeLPT results
examined, on average there has been a 93%
(range 85%-96%) agreement between the
BeLPT laboratories. Examining only posi-
tive BeLPT results shows a 30% (range
21%-38%) agreement among the labora-
tories on split-specimen testing. Table 6
also shows data collected concerning the
Table 5. Quality control BeLPTfindings, June 1991 to October 1994.
Quality control
laboratories BeLPT outcomea Concordance/tested % Concordance
A and B Positive BeLPTs 29/88 33
All BeLPTs 1076/1125 96
B and C Positive BeLPTs 11/29 38
All BeLPTs 268/299 90
A and C Positive BeLPTs 11/53 21
All BeLPTs 212/250 85
8Uninterpretable/indeterminate results, laboratory errors, insufficient cells, and single positive BeLPT results were
removed; therefore, the sum of BeLPTs with reportable results may not equal the total number of results received.
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Table 6. Positive BeLPT retest consistency, June 1991
to October 1994.
No. positive No. negative
Positive on first on first
BeLPT value BeLPT BeLPT retest %
range (n=222) (n=141) Reversion
1.6-2.9 61 54 88.5
3.0-4.9 62 52 83.9
5.0-9.9 40 21 52.5
10.0-19.9 26 9 34.6
20.0-49.9 17 5 29.4
.50.0 16 0 0.0
issue of false-positive BeLPT results. To
examine the potential for false positives
occurring, BeLPT-positive results were
compared with the outcome of confirma-
tional BeLPT testing. Positive BeLPT val-
ues were divided into six categories to
determine if the value of a positive BeLPT
result had any relationship to the rate with
which confirmational BeLPT results were
found to be positive or negative. A false-
positive rate of 88.5% was found between
initial BeLPT-positive values and confir-
mational BeLPT values when the initial
BeLPT value was less than 3.0. Rates
decreased until no false positives were
detected for initial BeLPT values greater
than 50.0.
ChestX-rays
A total of 4255 posterior/anterior chest
X-rays were evaluated according to the
ILO classification system for radiographs of
pneumoconioses by board certified radiolo-
gists who were certified B-readers. Findings
for the initial evaluation are shown in
Table 7. A total of 1 9 individuals had
abnormalities possibly associated with
CBD, profusion 1/0 or greater; and 869
Table 7. Posterior/anterior chest X-rays.
Findings No.
Total submitted for initial B-reader review 4255
Results of initial review
Normal 3267
Abnormal, not associated with CBD 869
Abnormal, possibly associated with CBD 119
Medical evaluation of abnormal chest
X-rays possibly associated with CBDR
CBD
Borderline BeLPT 1
Negative BeLPT 1
Sensitized (lavage BeLPT positive, 1
blood BeLPT negative)
Miscellaneous (normal, COPD, 97
emphysema, asbestosis, etc.)
COPD, chronic obstructive disease. an=100; 19 declined
medical evaluation.
had abnormalities not associated with
CBD, profusion 0/1 or less.
Abnormal findings included densities/
nodules/masses, pleural changes that may
have resulted from asbestos exposure, pre-
vious infections or trauma, pulmonary
hypertension, obstructive pulmonary dis-
ease, cardiac abnormalities, spinal abnor-
malities, and abnormalities of the major
blood vessels and diaphragm. The Rocky
Flats Medical Director sent letters to for-
mer employees recommending that they
contact their private physicians regarding
abnormal chest X-rays. Rocky Flats
Occupational Health physicians reviewed
abnormal findings with current employees.
Many of the abnormalities were resolved
upon review of previous chest X-rays in
conjunction with a repeat chest X-ray.
Ofthe chest X-rays for the 27 individu-
als diagnosed with CBD, only one had a
small opacity profusion of 1/0 or greater,
one had a small opacity profusion of 0/1,
and the remaining 25 were rated as 0/0.
For the 74 beryllium-sensitized cases, chest
X-ray results revealed three people with
small opacity profusion of 1/0 and one
with a small opacity profusion of 0/1; the
remaining 69 were rated as 0/0.
To date, only one case of CBD has
been identified in which chest X-ray
findings indicated CBD not already sug-
gested by the peripheral blood BeLPT. In
addition, one individual with a small opac-
ity profusion of 1/0 referred for evaluation
was found to be BAL BeLPT positive. No
indication of granulomatous disease was
found on biopsy. The peripheral blood
BeLPT results for this individual were pos-
itive on the initial draw. Since individuals
whose chest X-rays showed a small opacity
profusion of 1/0 or greater were referred
for CBD medical evaluations, the second
confirming BeLPT blood draw for this
individual was performed as part of the
CBD medical evaluation process. The
result of this confirming BeLPT was posi-
tive. This individual is listed as a presumed
case of CBD. Another individual who was
referred for medical evaluation as the result
ofa chest X-ray with a opacity profusion of
1/0 was peripheral blood BeLPT-negative,
but was found to be BAL-positive. This
individual was classified as beryllium sensi-
tized, and will be reevaluated annually for
CBD, since no evidence ofgranulomatous
disease was found on lung biopsy.
Table 8 lists the differences in radi-
ographic findings between the initial and
second B-reader review for 869 abnormal
chest X-rays not associated with CBD, 1 19
chest X-rays possibly associated with CBD
as determined by the initial B-reader
review, and 154 normal chest x-rays as
determined by the initial B-reader review.
Discussion
Demographics oftheBeryllium Health
Surveillance ProgramStudyPopulation
The number ofprogram participants tested
(n=4268) from June 1991 through
October 1994 was comprised of 42% cur-
rent employees and 58% former employees
of Rocky Flats. Nearly 50% (49.5%) of
current employees requested participation
in the BHSP, as did 78.5% of former
employees. Former employees apparently
had an increased level ofconcern regarding
exposure to beryllium and related health
effects. However, this increased participa-
tion rate might also have been because for-
mer employees had not previously had the
same opportunity to receive testing for
beryllium sensitivity as current employees.
The sensitization rate (CBD and sensi-
tized cases) for the population studied
(n=4268) was 2.3%. This rate is compara-
ble to the sensitization rate (CBD and sen-
sitized cases) for previously studied
beryllium-exposed populations (n=946) at
Rocky Flats, which was 2.5%. Previously
Table 8. Differences in findings between first and second B-reader review.
First reviewfindings No. Second review findings No. different % Different
Normal 154 Abnormal, not 20 13.0
associated with CBD
Normal 154 Abnormal, possibly 1 0.6
associated with CBD
Abnormal, not 869 Normal 116 13.3
associated with CBD
Abnormal, not 869 Abnormal, possibly 12 0.2
associated with CBD associated with CBD
Abnormal, possibly 119 Normal 7 5.9
associated with CBD
Abnormal, possibly 119 Abnormal, not 33 27.7
associated with CBD associated with CBD
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studied populations were selected from the
current employee workforce based upon a
significant opportunity for exposure to
beryllium. The BHSP study population is
comprised ofcurrent and former employees
with any level ofexposure to beryllium.
The statistically significant difference
found in the mean time from the first iden-
tified beryllium exposure to the diagnosis
of CBD or the identification of sensitiza-
tion between current and former employ-
ees might in part be an artifact ofthe order
in which individuals were offered testing.
Testing for former employees was delayed
until the majority of testing for current
employees had been completed. Other
causes for these differences might be
changes in testing methodology, changes in
the sensitivity of the BeLPT, and changes
in medical criteria for diagnosing CBD.
We recognize that the mean times between
the first identified beryllium exposure and
the diagnosis of beryllium sensitization or
CBD are only estimates, but nonetheless
they provide an estimate of the minimum
length of time that a beryllium-exposed
employee may have to be followed subse-
quent to exposure.
Posterior/Anterior ChestX-rays
The use of posterior/anterior chest X-rays
evaluated by B-reader radiologists, using
the ILO classification system for radi-
ographs of pneumoconioses, proved to be
an ineffective method of identifying
individuals for medical referral for CBD
evaluation. Of the 101 cases ofberyllium
sensitization and CBD identified during
this period, four individuals had a profu-
sion ofsmall opacities of 1/0 and three had
a profusion of 0/1. Of these, one case of
CBD was found with a profusion of small
opacities of 1/0. This person was referred
for a CBD medical evaluation because of
the chest X-ray findings. This individual
was found to be repeatedly peripheral
blood BeLPT negative, and lung lavage
BeLPT positive. However, biopsy revealed
no evidence of pulmonary granulomas.
This single case would most likely not have
been discovered without the chest X-ray
portion of the BHSP. The overall value of
posterior/anterior chest X-rays evaluated by
B-reader radiologists appears limited as a
means of identifying candidates for CBD
medical evaluations. The chest X-ray was
nonspecific for the diagnosis of CBD in
this population ofworkers. These observa-
tions are similar to those reported else-
where (4,8,9). Based on these data, the
posterior/anterior chest X-ray should not
be the sole means ofscreening for CBD or
beryllium sensitization in an occupational
beryllium health surveillance program.
In general, the variability between the
two B-reader radiology groups' evaluations
ofa random sample ofnormal chest X-rays
and all chest X-rays with an identified
abnormality was similar to that previously
reported (10). No reason was identified for
the variability (33.6%) between the first
radiology group's findings ofabnormalities
possibly associated with CBD and the
findings of the second radiology review.
However, the first group's opacity profu-
sion ratings were consistently higher than
those ofthe second.
Beryllium Lymphocyte Proliferation
TestQuality Control
The BHSP used a quality-control program
to monitor and verify BeLPT results. A
beryllium health surveillance program
based on the BeLPT should have a quality-
assurance program in place to monitor
test results.
The results of split-specimen testing
among the three laboratories showed 30%
agreement on positive BeLPTs. These
results were disappointing and clearly point
to the necessity for split-specimen testing
and repeat testing for positive and border-
line-positive BeLPT results. We believe
that differences in the technical procedures
for performing the BeLPT among the labo-
ratories are the principal reasons for the
differences seen in BeLPT quality control
results. Until standardized laboratory
methodology is used by BeLPT laborato-
ries, the ability to compare BeLPT results
among laboratories is suspect (11).
Possible reasons for the disagreement
between BeLPT results from different labo-
ratories are speculative, but can include
differences in technical procedures, differ-
ences in instrumentation, differences in lab-
oratory technician skill, handling procedures
for blood specimens, and laboratory experi-
ence level. Clearly this is a difficult assay
that requires considerable skill and experi-
ence to perform correctly. Temperature and
time are factors that can affect BeLPT
results. Maintaining blood specimens at
room temperature from the time of the
blood draw to receipt at the laboratory is an
important factor in maintaining theviability
of the blood cells (2). Similarly, the time
from the blood draw until receipt by the
laboratory is important. Previous investiga-
tions concerning cell viability showed that
no significant decrease in cell reactivity was
seen up to 24 hr afterthe blood draw (2).
TheBerylliumLymphocyte
ProliferationTest
The usefulness of the peripheral blood
BeLPT to monitor a beryllium exposed
population for the development of beryl-
lium sensitization and CBD was demon-
strated in the BHSP study population.
However, the BeLPT has limitations that
include the following: a) Because of the
potential for false-positive BeLPT results,
beryllium sensitization requires two con-
secutive or concurrent positive BeLPTs.
b) False-negative BeLPTs are known to
occur. c) At present only five commercial
or hospital laboratories are qualified to per-
form the BeLPT. d) The BeLPT must be
performed within 24 hr ofblood-specimen
collection. e) The lack of agreement
between laboratories on split-specimen
BeLPTs is common.
The need for BeLPT retesting has been
demonstrated through the identification of
10 cases of beryllium sensitization in indi-
viduals who previously tested normal.
These individuals had previously had
peripheral blood BeLPT negative results
between 1989 and 1991. One of these
individuals, following a medical evaluation,
has been diagnosed with CBD. Although
there is no standard for retesting, we have
established a 3-year retest frequency for
individuals who previously were negative
on the peripheral blood BeLPT. More fre-
quent retesting, for example annually, may
be recommended if prior clinical findings
or recent symptoms suggest CBD. These
10 sensitized retest cases represent either
BeLPT negative to positive conversions or
the identification of prior false-negative
BeLPT results. Analysis of these data
showed that the lower the value ofthe ini-
tial BeLPT positive, the greater the per-
centage of false positives identified as the
result ofconfirmational testing.
Beryllium Exposure:
Population at Risk
An evaluation of the job titles and work
histories of the beryllium-sensitized and
CBD cohorts suggests that exposure to
beryllium at levels below the threshold
limit value (TLV) of2.0 pg/m3 may result
in beryllium sensitization. This may be
particularly important for individuals who
are more sensitive to beryllium exposures
than the general population (12). The long
latency period for development of beryl-
lium sensitization or CBD and the poten-
tial for continued low-level exposures over
time make the determination ofa safe level
for beryllium exposure difficult.
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As the use of beryllium continues to
increase in aerospace, electronics, and a
variety ofother industries, the health sur-
veillance ofberyllium-exposed populations
becomes vitally important to occupational
physicians and to epidemiologists in occu-
pational settings. This investigation has
shown that the BeLPT is the most effective
method for detection of beryllium sensiti-
zation. It has also demonstrated that poste-
rior/anterior chest X-rays previously used
in beryllium health surveillance programs
are not effective as a sole screening tool.
Occupational physicians in industries that
use beryllium or beryllium alloys should
strongly consider the potential for employ-
ees to develop beryllium sensitization and
CBD even though routine health monitor-
ing is provided. It is important to recognize
that, for some employees, exposure to beryl-
lium at levels below the TLV might cause
disease. We have reported on a population
of employees in whom applicable safety
exposure requirements for beryllium were
maintained yet beryllium sensitization and
CBD occurred. We have also reported cases
ofsensitization and CBD in employees with
jobs that were thought not to be of con-
cern because oftheir minimal opportunity
for exposure to beryllium.
Lesons Leared
We have learned a number of lessons at
Rocky Flats regarding establishing and
maintaining a beryllium health surveillance
program. Some ofthese may have applica-
tion at other facilities where beryllium is
used. Of paramount importance is the
identification ofworkers exposed to beryl-
lium. Without considerable coordination
with supervisory and industrial hygiene per-
sonnel, groups ofexposed workers can be
missed or expensive medical monitoring can
be performed unnecessarily. Ifberyllium
operations are confined to specific areas
and access to these areas is limited, the
identification ofworkers needing monitor-
ing can be simplified and the costs ofsur-
veillance reduced. Since chest X-rays have
not been useful in identifying early disease,
they need not be routinely done. The
BeLPT can assist industry in demonstrat-
ing the adequacy of beryllium-exposure
control procedures. Unfortunately, because
of the typically low prevalence of CBD,
several years of testing are necessary to
document the control ofexposure.
The BHSP has provided, and will
continue to provide, important informa-
tion for occupational physicians and pri-
vate health-care professionals concerning
the design, implementation, and ongoing
management of a program for the detec-
tion ofberyllium sensitization and CBD in
populations at risk.
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